



Advances in DNA Vaccines

Guest Editors:

Dr. Maria G. Isaguliantis

1. Department of Research, Riga Stradins University, LV-1007 Riga, Latvia

2. Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden

Dr. Karl Ljungberg

Director of Preclinical Development, Eurocine Vaccines AB, Fogdevreten 2, Karolinska Institutet Science Park, 171 65 Solna, Sweden

Deadline for manuscript submissions:

closed (28 February 2019)

Message from the Guest Editors

DNA is a rapidly developing vaccine platform for cancer, infectious and non-infectious diseases. Plasmids use adjuvants to encode proteins to be further synthesized in vaccine recipients. DNA is mainly synthetic, ensuring enhanced expression. Their introduction into the host induces antibody and cellular responses. The latter are often more pronounced, and mimic the events occurring in infection, especially viral. Processing can be re-routed to the lysosome, or immunogen can be secreted for further presentation in a complex with MHC II. Apart from the expression, the vaccination efficacy depends on DNA delivery. The progress of research aiming at the optimization of DNA vaccine design, delivery, and immunogenic performance have led to a marked increase in their efficacy in large species and man. New DNA vaccines for use in the treatment of infectious diseases, cancer, allergies and autoimmunity are forthcoming. This Special Issue will deal with all aspects of DNA vaccine development.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com